Translesion polymerase η is upregulated by cancer therapeutics and confers anticancer drug resistance

Cancer Research

Volumn 74, Issue 19, 2014, Pages 5585-5596

  Tomicic, Maja T ^a   Aasland, Dorthe ^a   Naumann, Steffen C ^a   Meise, Ruth ^a   Barckhausen, Christina ^a   Kaina, Bernd ^a   Christmann, Markus ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA DIRECTED DNA POLYMERASE; DNA DIRECTED DNA POLYMERASE ETA; PROTEIN P53;

ANIMAL; DNA REPLICATION; DRUG RESISTANCE; HUMAN; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA REPLICATION; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICE, INBRED NOD; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84907546654     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0953     Document Type: Article

References (50)

1. Muniandy PA, Liu J, Majumdar A, Liu ST, Seidman MM. DNA interstrand crosslink repair in mammalian cells: step by step. Crit Rev Biochem Mol Biol 2010;45:23-49.
2. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009;6:638-47.
3. Ludlum DB. The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Invest 1997;15:588-98.
4. Pegg AE. Repair of O (6)-alkylguanine by alkyltransferases. Mutat Res 2000;462:83-100.
5. Tong WP, Kirk MC, Ludlum DB. Formation of the cross-link 1-[N3-deoxycytidyl), 2-[N1-deoxyguanosinyl]ethane in DNA treated with N, N'-bis (2-chloroethyl)-N-nitrosourea. Cancer Res 1982;42:3102-5.
6. Fischhaber PL, Gall AS, Duncan JA, Hopkins PB. Direct demonstration in synthetic oligonucleotides that N, N'-bis (2-chloroethyl)-nitrosourea cross links N1 of deoxyguanosine to N3 of deoxycytidine on opposite strands of duplex DNA. Cancer Res 1999;59:4363-8.
7. Brulikova L, Hlavac J, Hradil P. DNA interstrand cross-linking agents and their chemotherapeutic potential. Curr Med Chem 2012;19:364-85.
8. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25.
9. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012;13:879-86.
10. Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, et al. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010;16:5862-72.
11. Guida M, Cramarossa A, Fistola E, Porcelli M, Giudice G, Lubello K, et al. High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study. J Transl Med 2010;8:115.
12. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009;361:1475-85.
13. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: an update. Toxicology 2003;193:3-34.
14. Christmann M, Kaina B. Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res 2013;41:8403-20.
15. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007;28:739-45.
16. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999;18:7644-55.
17. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
18. Tomicic MT, Christmann M, Kaina B. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Cancer Res 2005;65:8920-6.
19. Tomicic MT, Christmann M, Kaina B. Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. J Pharmacol Exp Ther 2010;332:316-25.
20. Tomicic MT, Kaina B. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Biochim Biophys Acta 2013;1835:11-27.
21. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 2004;23:1283-90.
22. Batista LF, Roos WP, Christmann M, Menck CF, Kaina B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNAdouble-strand breaks. CancerRes 2007;67:11886-95.
23. Naumann SC, Roos WP, Jost E, Belohlavek C, Lennerz V, Schmidt CW, et al. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer 2009;100:322-33.
24. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 1998;8:17-23.
25. Barckhausen C, Roos WP, Naumann SC, Kaina B. Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair. Oncogene 2014;33:1964-74.
26. Hoffmann JS, Cazaux C. Aberrant expression of alternative DNA polymerases: a source of mutator phenotype as well as replicative stress in cancer. Semin Cancer Biol 2010;20:312-9.
27. Rey L, Sidorova JM, Puget N, Boudsocq F, Biard DS, Monnat RJ Jr, et al. Human DNA polymerase eta is required for common fragile site stability during unperturbed DNA replication. Mol Cell Biol 2009;29:3344-54.
28. Bergoglio V, Boyer AS, Walsh E, Naim V, Legube G, Lee MY, et al. DNA synthesis by Pol eta promotes fragile site stability by preventing underreplicated DNA in mitosis. J Cell Biol 2013;201:395-408.
29. Roos W, Baumgartner M, Kaina B. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 2004;23:359-67.
30. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003;22:8233-45.
31. Christmann M, Kaina B. Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents. J Biol Chem 2000;275:36256-62.
32. Christmann M, Tomicic MT, Aasland D, Berdelle N, Kaina B. Three prime exonuclease I (TREX1) is Fos/AP-1 regulated by genotoxic stress and protects against ultraviolet light and benzo (a) pyreneinduced DNA damage. Nucleic Acids Res 2010;38:6418-32.
33. Liu G, Chen X. DNA polymerase eta, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates the DNA damage checkpoint and p53 activation. Mol Cell Biol 2006;26:1398-413.
34. Tomicic MT, Friedrichs C, Christmann M, Wutzler P, Thust R, Kaina B. Apoptosis induced by (E)-5-(2-bromovinyl)-2'-deoxyuridine in varicella zoster virus thymidine kinase-expressing cells isdriven by activation of c-Jun/activator protein-1 and Fas ligand/caspase-8. Mol Pharmacol 2003;63:439-49.
35. Spanswick VJ, Hartley JM, Ward TH, Hartley JA. Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay. Methods Mol Med 1999;28:143-54.
36. Tomicic MT, Thust R, Sobol RW, Kaina B. DNA polymerase beta mediates protection of mammalian cells against ganciclovirinduced cytotoxicity and DNA breakage. Cancer Res 2001;61:7399-403.
37. Christmann M, Pick M, Lage H, Schadendorf D, Kaina B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 2001;92:123-9.
38. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733-7.
39. Andersen PL, Xu F, Ziola B, McGregor WG, Xiao W. Sequential assembly of translesion DNA polymerases at UV-induced DNA damage sites. Mol Biol Cell 2011;22:2373-83.
40. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node inthe battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 2007;6:1079-99.
41. Brent TP, Lestrud SO, Smith DG, Remack JS. Formation of DNA interstrand cross-links by the novel chloroethylating agent 2-chloroethyl (methylsulfonyl) methanesulfonate: suppression by O6-alkylguanine-DNA alkyltransferase purified from human leukemic lymphoblasts. Cancer Res 1987;47:3384-7.
42. Zheng H, Wang X, Warren AJ, Legerski RJ, Nairn RS, Hamilton JW, et al. Nucleotide excision repair- and polymerase eta-mediated errorprone removal of mitomycin C interstrand cross-links. Mol Cell Biol 2003;23:754-61.
43. Albertella MR, Green CM, Lehmann AR, O'Connor MJ. A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res 2005;65:9799-806.
44. Chen YW, Cleaver JE, Hanaoka F, Chang CF, Chou KM. A novel role of DNA polymerase eta in modulating cellular sensitivity to chemotherapeutic agents. Mol Cancer Res 2006;4:257-65.
45. Mogi S, Butcher CE, Oh DH. DNA polymerase eta reduces the gamma-H2AX response to psoralen interstrand crosslinks in human cells. Exp Cell Res 2008;314:887-95.
46. Kawamoto T, Araki K, Sonoda E, Yamashita YM, Harada K, Kikuchi K, et al. Dual roles for DNA polymerase eta in homologous DNA recombination and translesion DNA synthesis. Mol Cell 2005;20:793-9.
47. McIlwraith MJ, Vaisman A, Liu Y, Fanning E, Woodgate R, West SC. Human DNA polymerase eta promotes DNA synthesis from strand invasion intermediates of homologous recombination. Mol Cell 2005;20:783-92.
48. Sneeden JL, Grossi SM, Tappin I, Hurwitz J, Heyer WD. Reconstitution of recombination-associated DNA synthesis with human proteins. Nucleic Acids Res 2013;41:4913-25.
49. Soria G, Belluscio L, van Cappellen WA, Kanaar R, Essers J, Gottifredi V. DNA damage induced Pol eta recruitment takes place independently of the cell cycle phase. Cell Cycle 2009;8:3340-8.
50. Tucker MA, Meadows AT, Boice JD Jr., Stovall M, Oberlin O, Stone BJ, et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987;78:459-64.